Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30.CAR-EBVSTs in Relapsed or Refractory CD30-Positive Lymphomas
NCT04288726Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Sep 2020
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells, Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD30.CAR-EBVST cells in diffuse large B-cell lymphoma (DLBCL), extranodal NK/T-cell lymphoma (ENKTCL) and Hodgkin lymphoma (HL), sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity Rate at 28 days. Started Sep 2020; status: active, not recruiting.
02
Drugs
CD30.CAR-EBVST cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)extranodal NK/T-cell lymphoma (ENKTCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04288726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288726.